Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q96I13
UPID:
ABHD8_HUMAN
Alternative names:
Alpha/beta hydrolase domain-containing protein 8
Alternative UPACC:
Q96I13; Q9HAE9
Background:
Protein ABHD8, known as Alpha/beta hydrolase domain-containing protein 8, plays a crucial role in cellular processes with its enzymatic functions. Despite its significance, the specific functions remain to be fully elucidated, making it a subject of ongoing research.
Therapeutic significance:
Understanding the role of Protein ABHD8 could open doors to potential therapeutic strategies. Its involvement in cellular mechanisms suggests a potential for targeting in disease treatment, although direct associations with diseases are yet to be established.